IRICoR is pleased to announce the appointment of its Chief Executive Officer, Dr. Nadine Beauger, to Immune Biosolutions Board of Directors.
Immune Biosolutions is an early-stage biopharmaceutical company focused on the discovery, engineering and development of humanized chicken antibodies that target intractable membrane proteins with a validated therapeutic potential. Immune Biosolutions’ current pipeline of therapeutic programs includes antibody molecules against several GPCRs—traditionally difficult-to-target membrane proteins that are known to be over-expressed in several cancers.
“The Immune Biosolutions team leads insightful and highly innovative research. It is exciting for me to join the Board of such a dynamic group. I look forward to sharing my insights about the development of new therapeutic pipelines in oncology and immunology based on the company’s technology,” noted Dr. Beauger.
To read the news